Œ¤‹†ŽÀÑ

ŽŽŒ±•Ê

ŽŽŒ±–¼ ŽŽŒ±–¼i‰pŒêj Œ¤‹†‘ã•\ŽÒ/Œ¤‹†Ž––±‹Ç ”­•\E˜_•¶
TORG0301
ŠùŽ¡—Ϭ×–E”xŠà‚ɑ΂·‚鉖Ž_ƒAƒ€ƒ‹ƒrƒVƒ“‚Ì‘æ‡U‘ŠŽŽŒ±
Phase II Study of Amrubicin, A New Active Drug in Refractory or Relapsed Small-Cell Lung Cancer ‰¡•lŽs—§Žs–¯•a‰@ ŒÄ‹zŠí“à‰ÈF“n糌Îu˜Y 2006-JCO
2006-ASCO
2006-ESMO
2006-ŠàŽ¡
2006-”xŠà
2009-ASCO
TORG0502
‚—îŽÒ–¢Ž¡—Ôñ¬×–E”xŠà‚ɑ΂·‚é S-1‚ƃQƒ€ƒVƒ^ƒrƒ“•¹—p‚̗Տ°‘æ‡T/‡U‘ŠŽŽŒ±
A combination phase I / II study of gemcitabine with S-1 for previously untreated elderly patients with non-small cell lung cancer “ŒŠC‘åŠwˆãŠw•”“à‰ÈŠwŒnŽîᇓà‰ÈF]Œû Œ¤“ñ /‹ãB‚ª‚ñƒZƒ“ƒ^[ŒÄ‹zŠí‰È F£ŒË ‹MŽi 2007-JTO
2007-ASCO
2007-IASLC
2008-ASCO
2010-Lung Cancer
TORG0503
Š®‘SØœ‚³‚ꂽ”ñ¬×–E”xŠà‚ɑ΂·‚épŒã•â•‰»Šw—Ö@ ‚Æ‚µ‚ẴpƒNƒŠƒ^ƒLƒZƒ‹/ƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“•¹—p—Ö@‚ƃhƒZƒ^ƒLƒZƒ‹/ƒVƒXƒvƒ‰ƒ`ƒ“•¹—p—Ö@‚Æ‚Ì ƒ‰ƒ“ƒ_ƒ€‰»‘æ‡U‘ŠŽŽŒ±
A Randomized Phase II Trial of Adjuvant Chemotherapy with Docetaxel (DOC) plus Cisplatin (CIS) versus Paclitaxel (PAC) plus Carboplatin (CAR) in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC) ‰¡•lŽs—§Žs–¯•a‰@ ŒÄ‹zŠí‰ÈF“n糌Îu˜Y/‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ ŒÄ‹zŠí‰ÈF‹v•Û“cŠ] 2009-ASCO
2009-”xŠà
2010-ESMO
2011-IASLC
2014-JSMO
TORG0604
‚—îŽÒ‚ÌŒÀ‹ÇŒ^¬×–E”x‚ª‚ñ‚ɑ΂·‚éƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“{ƒCƒŠƒmƒeƒJƒ“•¹—p—Ö@‚¨‚æ‚Ñ’€ŽŸ‹¹•”•úŽËüŽ¡—Â̑æ‡T/‡U‘ŠŽŽŒ±
Phase I/II trial of carboplatin plus CPT-11 chemotherapy with accelerated hyperfractionated radiotherapy for elderly patients with limited stage small cell lung cancer ‰¡•lŽs—§Žs–¯•a‰@ ŒÄ‹zŠí“à‰ÈF‰ª–{_–¾/‰¡•lŽs—§Žs–¯•a‰@ ŒÄ‹zŠí“à‰ÈFŽOŠp—S¶ 2008-ŠàŽ¡iP‡Tj
2009-ŒÄ‹zŠíiP‡Tj
2009-”xŠàiP‡Tj
2014-ESMO
2015-ŒÄ‹zŠí
2015-WCLC
2015-ŠàŽ¡
2016-JSMO
2016-ESMO
TORG0705
ƒvƒ‰ƒ`ƒi‘ϐ« / Ä”­”ñ¬×–E”xŠà‚ɑ΂·‚éS-1‚ƃQƒ€ƒVƒ^ƒrƒ“•¹—p‚̗Տ°‘æ‡U‘ŠŽŽŒ±
A combination phase II study of gemcitabine and S-1 for platinum-refractory patients with non-small cell lung cancer ç—t‘åŠwˆãŠw•”•‘®•a‰@ ŒÄ‹zŠí“à‰È F‘êŒû—Tˆê 2009-”xŠà
2009-IASLC
2010-ASCO
2011-JTO
TORG0706
œ“]ˆÚ‚ð—L‚·‚éis”ñ¬×–E”xŠà‚ɑ΂·‚éƒ]ƒŒƒhƒƒ“Ž_‚̍œ‘ãŽÓƒ}[ƒJ[‚Å‘w•Ê‰»‚µ‚½ƒ‰ƒ“ƒ_ƒ€‰»”äŠrŽŽŒ±
Randomized trial of platinum based combination chemotherapy with or without Zoledronic acid as first line therapy for non-small cell lung cancer with bone metastases stratified by bone marker ‚ª‚ñŠ´õÇƒZƒ“ƒ^[“s—§‹îž•a‰@ ŒÄ‹zŠí“à‰ÈFàF’J¹•F/‚ª‚ñŠ´õÇƒZƒ“ƒ^[“s—§‹îž•a‰@ ŒÄ‹zŠí“à‰ÈF×Œ©K¶ Žg—p¬Ñ’²¸(1017)‚֕ύX
TORG0808
ƒvƒ‰ƒ`ƒi»Ü‚ðŠÜ‚Þ‘OŽ¡—×ð‚Ì‚ ‚éis”ñ¬×–E”xŠà‚ɑ΂·‚é 2nd line‚à‚µ‚­‚Í3rd lineŽ¡—ÂƂµ‚Ä‚Ìerlotinib/S-1•¹—p—Ö@‚Ì‘æI‘ŠŽŽŒ±
A combination phase I study of erlotinib and S-1for platinum-refractory patients as the 2nd or 3rd-line treatment for advanced non-small cell lung cancer Žl‘‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰È FVŠC “N/ Žl‘‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰ÈF–ìã ®”VA‰¬–ì “ÖŽq 2009-ŠàŽ¡
2009-”xŠà
TORG0809
•a—•aŠú‡U-‡VAŠú”ñ¬×–E”xŠàŠ®‘SØœ—á‚ɑ΂µ‚ăVƒXƒvƒ‰ƒ`ƒ“^ƒhƒZƒ^ƒLƒZƒ‹‚ÌŒã‚ÉTS-1‚̈ێ—Ö@‚ðs‚¤ pŒã•â•‰»Šw—Ö@‚Ìfeasibility study
Feasibility trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CDDP) followed by maintenance chemotherapy of S-1 in completely resected non-small cell lung cancer (NSCLCj “Œ‹žˆã‰È‘åŠw•a‰@ ŒÄ‹zŠíEbó‘BŠO‰ÈF’r“c“¿•F/‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ ŒÄ‹zŠí“à‰ÈFm•Û½Ž¡ 2012-ASCO
2012-ŠàŽ¡
2012-”xŠà
2012-JSMO
2013-BJC
2016-ESMO
TORG0910
Øœ•s”\IIIŠúE‡WŠú‚Ì”xG•½ã”çŠà‚ɑ΂·‚éƒlƒ_ƒvƒ‰ƒ`ƒ“+‰–Ž_ƒCƒŠƒmƒeƒJƒ“‚Ì‘½Ž{Ý‘æ‡U‘ŠŽŽŒ±
Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung cancer _“ސ쌧—§‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí‰È FŽR“c kŽO/_“ސ쌧—§‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí‰È FÖ“¡t—m 2014-JSMO
2014-”xŠà
2015-Anticancer Research
TORG0911
ã”琬’·ˆöŽqŽó—e‘́iEGFRjˆâ“`Žq•ÏˆÙ—z«‚Ì Ä”­Eis”ñ¬×–E”xŠà‚ɑ΂·‚éerlotinib‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢ - ’á—p—Ê•]‰¿ŽŽŒ± -
A Prospective, Multi-center Phase II Trial on the Efficacy and Safety of Low-dose Erlotinib Monotherapy for Patients with EGFR Mutation-positive, Previously Treated Non-small Cell Lung Cancer ŽOˆä‹L”O•a‰@ ŒÄ‹zŠí“à‰ÈFš “ª‰p•v2011-ŠàŽ¡
2013-WCLC
2013-”xŠà
2014-ASCO
2015-EJC
TORG0912
”ñ¬×–E”x‚ª‚ñŠ³ŽÒ‚̑̏d‚¨‚æ‚ÑQOL“™‚ÉŠÖ‚·‚é—Տ°Œ¤‹†
Japan Nutrition and QOL survey in patients with advanced non-small cell Lung Cancer study ’é‹ž‘åŠwˆãŠw•”•‘®•a‰@ ŒÄ‹zŠí“à‰ÈF]ŒûŒ¤“ñ/“Á’è”ñ‰c—˜Šˆ“®–@l‹¹•”ŽîᇗՏ°Œ¤‹†‹@\F¬“‡Š°”V 2011-ŠàŽ¡
2011-”xŠà
2012-ESMO
2012-”xŠà
2012-JSMO
2012-ŠàŽ¡
TORG0913
ã”琬’·ˆöŽqŽó—e‘́iEGFRjˆâ“`Žq•ÏˆÙ‰A«‚̍Ĕ­Eis”ñ¬×–E”xŠà‚ɑ΂·‚éerlotinib/S-1•¹—p—Ö@‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢- ‘æ‡U‘ŠŽŽŒ±-
A phase II study of erlotinib/S-1 combination therapy in patients with recurrent or advanced non-small lung cancer who do not possess active EGFR mutation. Žl‘‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰ÈFVŠC“N/Žl‘‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰ÈF–ìã®”VAãŒŽ–«K 2012-ASCO
2012-”xŠà
2012-JSMO
2013-WCLC
TORG1014
‚—îŽÒis”ñ¬×–E”xŠà‚ɑ΂·‚éDocetaxel/Bevacizumab•¹—p—Ö@‚ÌŒŸ“¢ - Feasibility study -
Feasibility study of docetaxel and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer ‚ª‚ñŠ´õÇƒZƒ“ƒ^[“s—§‹îž•a‰@ ŒÄ‹zŠí“à‰ÈFàF’J¹•F/‚ª‚ñŠ´õÇƒZƒ“ƒ^[“s—§‹îž•a‰@ ŒÄ‹zŠí“à‰ÈF×Œ©K¶A‚–Ø—Y—º 2013-JSMO
2013-WCLC
2013-”xŠà
2015-BMC@Cancer
TORG1015
‚—îŽÒis”ñ¬×–E”xŠà‚ɑ΂·‚éPemetrexed/Bevacizumab•¹—p—Ö@‚ÌŒŸ“¢ - Feasibility study -
Feasibility study of pemetrexed (PEM) plus bevacizumab (BV) as the first-line treatment for elderly advanced or recurrent non-squamous (non-Sq) non-small cell lung cancer (NSCLC) Žl‘‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰ÈFVŠC“N/Žl‘‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰ÈF–ìã®”VAãŒŽ–«K 2013-ASCO
2013-JSMO
2013-ŠàŽ¡
2013-WCLC
2013-”xŠà
2016-BMC@Cancer
TORG1016
G•½ã”炪‚ñ‚ðœ‚­isEÄ”­”ñ¬×–E”x‚ª‚ñ‚ɑ΂·‚é ƒhƒZƒ^ƒLƒZƒ‹/ƒVƒXƒvƒ‰ƒ`ƒ“/ƒxƒoƒVƒYƒ}ƒu•¹—p‘æII‘ŠŽŽŒ±
Phase II study of bevacizumab, cisplatin and docetaxel plus maintenance bevacizumab as first line treatment for patients with advanced non-small cell lung cancer (n-Sq NSCLC) combined with exploratory analysis of circulating cells (CEC) _“ސ쌧—§zŠÂŠíŒÄ‹zŠí•aƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰ÈF¬‘q‚Žu/_“ސ쌧—§zŠÂŠíŒÄ‹zŠí•aƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰ÈF‰Á“¡WŽj 2012-”xŠà
2013-ESMO
2013-WCLC
2014-JJCO
2014-ŒÄ‹zŠí
TORG1017
œ“]ˆÚ‚ð—L‚·‚é”ñ¬×–E”xŠà‚É‚¨‚¯‚é ƒ]ƒŒƒhƒƒ“Ž_‚ÌŽg—pŽÀ‘Ô’²¸
Multicenter study of zoledronic acid in lung cancer patients with bone metastasis. ‚ª‚ñEŠ´õÇƒZƒ“ƒ^[“s—§‹îž•a‰@ ŒÄ‹zŠí“à‰ÈFàF’J¹•F/‚ª‚ñEŠ´õÇƒZƒ“ƒ^[“s—§‹îž•a‰@ ŒÄ‹zŠí“à‰ÈF×Œ©K¶ 2013-WCLC
TORG1018
ªŽ¡ÆŽË‰Â”\IIIŠú”ñ¬×–E”xŠà‚ɑ΂·‚éƒVƒXƒvƒ‰ƒ`ƒ“{TS-1{TRT•¹—p—Ö@‚ƃVƒXƒvƒ‰ƒ`ƒ“{ƒhƒZƒ^ƒLƒZƒ‹{TRT•¹—p—Ö@‚̃‰ƒ“ƒ_ƒ€‰»‘æII‘ŠŽŽŒ± (TORG1018)
A randomized phase II study of cisplatin+TS-1 versus cisplatin+docetaxel, with thoracic radiotherapy for locally advanced non-small cell lung cancer ‰¡•lŽs—§Žs–¯•a‰@ ŒÄ‹zŠí“à‰ÈF‰ª–{_–¾/‰¡•lŽs—§Žs–¯•a‰@ ŒÄ‹zŠí“à‰ÈF‰ºìP¶ 2015-”xŠà
2016-JSMO
2016-WCLC
2016-ESMO
TORG1319
ƒQƒtƒBƒ`ƒjƒu‚É‚æ‚éˆêŽŸŽ¡—Ã’†‚É•a¨‚ªis‚µ‚½ã”瑝BˆöŽqŽó—e‘̈â“`Žq•ÏˆÙ—z«‚̋ǏŠis–”‚Í“]ˆÚ«”ñ¬×–E”xŠàŠ³ŽÒ‚ð‘Ώۂɉ»Šw—Ö@‚ƃQƒtƒBƒ`ƒjƒu‚Ì•¹—p‚ð­‚È‚­‚Æ‚à3ƒŒƒWƒƒ“Œp‘±‚µ‚½Žž‚Ì—LŒø«‹y‚шÀ‘S«‚ð‰»Šw—Ö@’P“Æ‚Æ”äŠr‚·‚鑽Ž{Ý‹¤“¯–³ìˆ×‰»‘æ‡U‘ŠŽŽŒ±
Randomized phase‡U trial evaluating the efficacy and safety of standard care {/| continuous gefitinib treatment beyond progression in patients with advanced@NSCLC after 1st line treatment with gefitinib ’é‹ž‘åŠwˆãŠw•”•‘®•a‰@ “à‰ÈŠwuÀŽîᇓà‰ÈF]ŒûŒ¤“ñ/’é‹ž‘åŠwˆãŠw•”•‘®•a‰@ “à‰ÈŠwuÀŽîᇓà‰ÈFŠÖ‡•F -
TORG1320
ã”琬’·ˆöŽqŽó—e‘́iEGFRjˆâ“`Žq•ÏˆÙ‰A«‚ÌŠùŽ¡—ÐisEÄ”­”ñ¬×–E”xŠà‚ɑ΂·‚éƒAƒ€ƒ‹ƒrƒVƒ“iAMRj{ƒGƒ‹ƒƒ`ƒjƒuiERLj—Ö@‚̈À‘S«‚Æ—LŒø«‚ÌŒŸ“¢- Phase II Study-
Multicenter phase II study of amrubicin plus erlotinib in non-smokers with previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor –k—¢‘åŠw•a‰@ ŒÄ‹zŠí“à‰ÈF‰v“c“TK/–k—¢‘åŠw•a‰@ ŒÄ‹zŠí“à‰ÈF‘å’JçŽq -
TORG1321
EGFRˆâ“`Žq•ÏˆÙ‰A«is”ñG•½ã”ç”ñ¬×–E”xŠà‚ɑ΂·‚éƒVƒXƒvƒ‰ƒ`ƒ“{ƒyƒƒgƒŒƒLƒZƒh{ƒxƒoƒVƒYƒ}ƒu•¹—p—Ö@Œã‚̈ێ—Ö@‚Æ‚µ‚ăyƒƒgƒŒƒLƒZƒh‚ƃyƒƒgƒŒƒLƒZƒh{ƒxƒoƒVƒYƒ}ƒu‚ð”äŠr‚·‚郉ƒ“ƒ_ƒ€‰»‘æ‡U‘ŠŽŽŒ±
Multicenter randomized phase II study of cisplatin+pemetrexed+bevacizmab followed by maintenance pemetrexied with or without bevacizmab in patients chemoterapy-naive advanced non-squamous non-small cell lung cancer with wild type EGFR ’؈ä•a‰@ ŒÄ‹zŠí“à‰ÈFX´Žu/“È–ØŒ§—§‚ª‚ñƒZƒ“ƒ^[ ŒÄ‹zŠí“à‰ÈFŠ}ˆä® -
TORG1322
‚—îŽÒis”xG•½ã”çŠà‚ɑ΂·‚éƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“AƒAƒuƒ‰ƒLƒTƒ“•¹—p‰»Šw—Ö@‚Ì‘æ‚P/‚Q‘ŠŽŽŒ±
Combination chemotheraoy of abraxane and carboplatin in elderly patients with advanced squamous cell lung cancer, phase 1/2 study ‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@ ŒÄ‹zŠí“à‰ÈF‘å]—Tˆê˜Y/‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ ŒÄ‹zŠí“à‰ÈF‘P‰Æ‹`‹MA”~‘º–ÎŽ÷Am•Û½Ž¡ -
TORG1323
‚—îŽÒi75ÎˆÈãjisÄ”­”ñG•½ã”ç”ñ¬×–E”xŠà‚ɑ΂·‚éƒhƒZƒ^ƒLƒZƒ‹+ƒxƒoƒVƒYƒ}ƒu—Ö@‚ƃyƒƒgƒŒƒLƒZƒh+ƒxƒoƒVƒYƒ}ƒu—Ö@‚Ì–³ìˆ×‰»‘æ‡U‘ŠŽŽŒ±
Randomized@phase@‡U@study@of@docetaxel@+@bevacizumab@or@pemetrexed@+@bevacizumab@for@elderly@non]squamous@non-small-cell@lung@cancer Ã“ì“Œ•”‘‡•a‰@@ŽîᇃZƒ“ƒ^[FVŠC“N/Žl‘‚ª‚ñƒZƒ“ƒ^[@ŒÄ‹zŠí“à‰ÈF–ìã®”VAãŒŽ–«K 2015-WCLC
TORG1424
‰»Šw—Ö@–¢Ž{sIIIB/IVŠú”ñG•½ã”ç”ñ¬×–E”xŠà‚ɑ΂·‚éPaclitaxel{Carboplatin{Bevacizumab•¹—p—Ö@‚Ì‘æI/II‘ŠŽŽŒ±
Phase 1/2 study of triple combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for chemotherapy-naïve stageIIIB/IV non- squamous non-small-cell lung cancer ‰ªŽR‘åŠw•a‰@@ƒAƒŒƒ‹ƒM[“à‰ÈF–؉YŸs/Žl‘‚ª‚ñƒZƒ“ƒ^[@ŒÄ‹zŠí“à‰ÈF–ìã®”V/‰ªŽR‘åŠw•a‰@@ŒÄ‹zŠíƒAƒŒƒ‹ƒM[“à‰ÈF‹v•ÛŽõ•v 2016-WCLC
2016-ESMO-Asia
TORG1425
Frailty‚ð—L‚·‚éEGFRˆâ“`Žq•ÏˆÙ—z«Ä”­Eis”ñ¬×–E”x‚ª‚ñ‚ɑ΂·‚é’á—p—Êerlotinib‚Ì‘æII‘ŠŽŽŒ±
A Prospective, Multi-center Phase II Trial on the Efficacy and Safety of Low-dose Erlotinib Monotherapy for Frail Patients with EGFR Mutation-positive, Non-small Cell Lung Cancer ‹v—¯•Ä‘åŠw•a‰@ ŒÄ‹zŠí“à‰ÈFŽR“cˆê•F/“ú–{Ô\ŽšŽÐˆã—ÃZƒ“ƒ^[ ‰»Šw—Ö@“à‰ÈF‹{–{MŒá -
TORG1426
Performance@StatusiPSj‚Qis”ñ¬×–E”xŠà‚ɑ΂·‚éƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“AƒAƒuƒ‰ƒLƒTƒ“•¹—p‰»Šw—Ö@‚Ì‘æ‡U‘ŠŽŽŒ±
Phase 2 study of Carboplatin plus nab-Paclitaxel for patients with PS 2 advanced NSCLC. ’é‹ž‘åŠwˆãŠw•”•‘®•a‰@@Žîᇓà‰ÈFŠÖ@‡•F/’é‹ž‘åŠwˆãŠw•”•‘®•a‰@@Žîᇓà‰ÈFŽsì–õŽq 2016-JSMO
2016-WCLC
TORG1528
‚—îŽÒi“WŒ^¬×–E”x‚ª‚ñ‚ɑ΂·‚éƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“+ƒGƒgƒ|ƒVƒh•¹—p—Ö@iCE—Ö@j‚ƃJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“+ƒCƒŠƒmƒeƒJƒ“•¹—p—Ö@iCI—Ö@j‚̃‰ƒ“ƒ_ƒ€‰»”äŠr‘æ‡U/‡V‘ŠŽŽŒ±
Comparing Carboplatin and Irinotecan(CI) with Carboplatin and Etoposide(CE) for the Treatment of Elderly Extended-Stage Small-Cell Lung Cancer ‰¡•lŽsŽs—§Žs–¯•a‰@@ŒÄ‹zŠí“à‰ÈF‰ª–{_–¾/‰¡•lŽs—§Žs–¯•a‰@@ŒÄ‹zŠí“à‰ÈF‰ºìP¶/ŽOŠp—S¶ -

”N“x•Ê

2006”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0301 Journal of Clinical OncologyiJCOj Volume24.Number34.Pages5448-5453.December1.2006 Sayaka Onoda Noriyuki Masuda, Takashi Seto, Kenji Eguchi, Yuichi Takiguchi, Hiroshi Isobe, Hiroaki Okamoto, Takashi Ogura, Akira Yokoyama, Nobuhiko Seki, Yoshiko Asaka-Amano, Masao Harada, Akihiro Tagawa, Hiroshi Kunikane, Masanori Yokoba, Kazutsugu Uematsu, Takayuki Kuriyama, Yumi Kuroiwa , Koshiro Watanabe
2006 ASCO”7060 T.Seto N.Masuda, Y.Takiguchi, H.Isobe, H.Okamoto, T.ogura, A.Yokoyama, K.Watanabe, K.eguchi,
31th ESMO 2006 #735PD Yuichi Takiguchi Noriyuki Masuda, Takashi Seto, Kenji Eguchi, , Hiroshi Isobe, Hiroaki Okamoto, Takashi Ogura, Akira Yokoyama, Koshiro Watanabe
‘æ44‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï ’Ë“c—TŽq ‰¡ŽR»A£ŒË‹MŽiA‘êŒû—TˆêA‰v“c“TKA]ŒûŒ¤“ñAˆé•”GA‰ª–{_–¾A¬‘q‚ŽuA“n糌Îu˜Y
‘æ47‰ñ“ú–{”xŠàŠw‰ïP-477 Œ´“c^—Y £ŒË‹MŽiA’Ë“c—TŽqA‘êŒû—TˆêA‰v“c“TKA]ŒûŒ¤“ñA‰¡ŽR»A¬‘q‚ŽuA‰ª–{_–¾A“n糌Îu˜Y
2007”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0502 2007 ASCO”18137 T.Seto, T.Yamanaka, K.Eguchi, H.Okamoto, M.shibuya, T.Shinkai, Y.Takiguchi, N.Masuda, Y.Ichinose, K.Watanabe
10th WCLCiIASLCj Seki, Nobuhiko Seto, Takashi; Okamoto, Hiroaki; Ogura, Takashi; Shibuya, Masahiko; Takiguchi, Yuichi; Shinkai, Tetsu; Masuda, Noriyuki; Watanabe, Koshiro
2008”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0502 2008 ASCO”19050 T.Seto T.Yamanaka, H.Okamoto, T.Ogura, M.Takiguchi, N.Masuda, T.Shinkai, Y.Ichinose, K.Watanabe
TORG0604 ‘æ46‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï —P–؍Ž•F ‰ª–{_–¾A×Œ©K¶AàF’J¹•FA”¨Î—²Ž¡A‰v“c“TKA‹g‘º–M•FAŠÝˆê”nA‚‹´—Ç•½A¼ì³Œ›A\‰Í—eŽqA’ÅŒ´~A¬‘q‚ŽuA“¡ˆä’m‹IAžw“c’¼–çA‘Œ“_ŽkA’Ò‘ºŽüŽqA“Œ—zˆê˜YA“n糌Îu˜Y
2009”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0301 2009 ASCO”8104 T.Seto T.Yamada, N.Masuda, K.Eguchi, Y.Takiguchi, H.Okamoto, T.Ogura, A.Yokoyama, Y.ichinose, K.Watanabe,
TORG0503 2009 ASCO”7561 K.Kubota H.Kunitoh, T.Seto, N.Shimada, M,Okamoto, N,Masuda, R.Maruyama, M.Shibuya, K.Watanabe
‘æ50‰ñ“ú–{”xŠàŠw‰ï‘‰ï WS3-4 š “ª‰p•v ‹v•Û“cŠ]A£ŒË‹MŽiA“‡“c’¼Ž÷A’؈䐳”ŽA‰ª–{_–¾A‰v“c“TKAŠÛŽR—ˆê˜YAàF’J¹•FA“n糌Îu˜Y
TORG0604 ‘æ49‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï —P–؍Ž•F ‰ª–{_–¾A×Œ©K¶A”¨Î—²Ž¡AŠÝˆê”nA¼ì³Œ›A\‰Í—eŽqA’ÅŒ´~A‰Á“¡WŽjA‘q“c•ó•ÛA•›“‡Œ¤‘¢AÎâ²•qA“¡ˆä’m‹IAžw“c’¼–çA’Ò‘ºŽüŽqA“n糌Îu˜Y
‘æ50‰ñ“ú–{”xŠàŠw‰ï‘‰ï WS6-5 ‰Á“¡WŽj ¬‘q‚ŽuA‰ª–{_–¾AàF’J¹•FA‰v“c“TKAŠÝˆê”nA‘q“c•ó•ÛA¼ì³Œ›A’ÅŒ´~A¼“ˆ“ցA‹´ê—eŽqA—P–؍Ž•FA“n糌Îu˜Y
TORG0705 ‘æ50‰ñ“ú–{”xŠàŠw‰ï‘‰ï O-164 ‘êŒû—Tˆê £ŒË‹MŽiAˆê£KlA–ìã®”VAVŠC“NA‰ª–{_–¾A–©_ˆêAŠÖ‡•FAŠÝˆê”nA¼ì³Œ›A“n糌Îu˜Y
12th WCLCiIASLCj Yuichi Takiguchi Takashi Seto, Yukito Ichinose, Naoyuki Nogami, Koichi Minato, Naohiko Seki, Kazuma Kishi, Masanori Nishikawa, Koshiro Watanabe
TORG0808 ‘æ47‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï OS61-5 –ìã®”V ‰¬–ì“ÖŽqA‰Á“¡—L‰ÁAVŠC“NA×Œ©K¶A“¡ˆä’m‹IAŽOŠp—S¶A‰ª–{Ž÷AˆäŒû–œ—¢A¬–ì‘òç‰ÀAžw“c’¼–çA‰ª–{_–¾AàF’J¹•FA™“c–«A“n糌Îu˜Y
‘æ50‰ñ“ú–{”xŠàŠw‰ï‘‰ï O-165 ×Œ©K¶ ˆäŒû–œ—¢AàF’J¹•FA–ìã®”VA‰¬–ì“ÖŽqA‰Á“¡—L‰ÁAVŠC“NA“¡ˆä˜a‹IAŽOŠp—S¶Ažw“c’¼–çA‰ª–{_–¾A™“c–«A“n糌Îu˜Y
2010”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0502 lung Cancer Volume69 .Issue2 Pages213-217.August2010 Takashi Seto Takeharu Yamanaka, Izumi Wasada, Nobuhiko Seki, Hiroaki Okamoto, Takashi Ogura, Masahiko Shibuya, Yuichi Takiguchi, Tetsu Shinkai, Noriyuki Masuda, Yukito Ichinose, Kenji Eguchi, Koshiro Watanabe
TORG0503 35th ESMO 2010 #4081 T.Kometani H.Kunitoh, N.Shimada, H.Okamoto, N.Masuda, R.Maruyama, M.Shibuya, K.Kubota, M.Tsuboi, K.Watanabe
TORG0705 2010 ASCO”e18007 Y.Takiguchi T.Seto, Y.Ichinose, N.Nogami, H.Okamoto, K.Minato, N.Seki, K.Kishi, M.Nishikawa, K.Watanabe
2011”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0503 13th WCLCiIASLCj T.Ohira K.Kubota, T.Seto, H.Kunitoh, N.Shimada, N.Ikeda, M.Tsuboi, H.Okamoto, N.Masuda, R.Maruyama, M.Shibuya, K.Watanabe
TORG0705 Journal of Thoracic Oncology(JTOj Volume6 Number1 January2011 P156-160 Takiguchi, Yuichi Seto, Takashi; Ichinose, Yukito; Nogami, Naoyuki; Shinkai, Tetsu; Okamoto, Hiroaki; Minato, Koichi ; Seki, Nobuhiko; Eguchi, Kenji; Kishi, Kazuma; Nishikawa, Masanori; Watanabe, Koshiro
TORG0912 ‘æ49‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï OS15-6 ”ó‰Y“O “c’†—mŽjAˆ¢•”“OÆAÎ“cWA×ˆä–qA¬oŒbŽqA‰¡ŽR»A]ŒûŒ¤“ñA“n糌Îu˜Y
‘æ52‰ñ“ú–{”xŠàŠw‰ï‘‰ï O-56 ‘êŒû—Tˆê ‘½“c—TŽiAä“cŒb”üŽqA‰¡ŽR‘ô–AÂ]Œ[‰îA‰ª–{_–¾AâV“¡”ŽA‚ŽR_ˆêA‘å‹´–õ—YA“n糌Îu˜YA]ŒûŒ¤“ñ
2012”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0809 2012 ASCO”7012 S. Niho K. Suzuki, H. Sakai, T. Kaburagi, T. Koike, K. Minato, T. Kato, H. Okamoto, T. Seto, Y. Hosomi, K. Shimizu, F. Oshita, M. Tsuchida, M. Yamashita, O. Kawashima, K. Kishi, H. Kunitoh, M. Takeuchi., K. Watanabe, N. Ikeda.
‘æ50‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï ’r“c“¿•F —é–ØŒ’ŽiAm•Û½Ž¡AŽðˆä—mA“L–؍F”VA¬’r‹P–¾A–©_ˆêA‰Á“¡WŽjA‰ª–{_–¾A£ŒË‹MŽiA×Œ©K¶A’؈䐳”ŽA’|“à³OA“n糌Îu˜Y
‘æ53‰ñ“ú–{”xŠàŠw‰ï‘‰ï WS1-3 ‚Žˆê–î m•Û½Ž¡A—é–ØŒ’ŽiAŽðˆä—mA’؈䐳”ŽA’|“à³OA“n糌Îu˜YA’r“c“¿•F
‘æ10‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï Œû‰‰17 02-014 Žðˆä—m —é–ØŒ’ŽiAm•Û½Ž¡A’r“c“¿•FA“L–؍F”VA¬’r‹P–¾A–©_ˆêA‰Á“¡WŽjA‰ª–{_–¾A£ŒË‹MŽiA×Œ©K¶A’؈䐳”ŽA“n糌Îu˜YA’|“à³O
TORG0912 37th ESMO 2012 ”1449 S.Atagi F. Imamura, A. Yokoyama, K. Minato, T. Harada, N. Katakami, T. Yokoyama, Y. Ohashi, K. Watanabe, K. Eguchi
‘æ53‰ñ“ú–{”xŠàŠw‰ï‘‰ï O-532 •ÐãM”V ˆÀ‘îM“ñA¡‘º•¶¶A‰¡ŽR»A–©_ˆêAŒ´“c•q”VA‘å‹´–õ—YA]ŒûŒ¤“ñA“n糌Îu˜Y
‘æ10‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï WS7-6 Œ´“c •q”V ˆÀ‘îM“ñA¡‘º•¶¶A‰¡ŽR»A–©_ˆêA‘å‹´–õ—YA]ŒûŒ¤“ñA“n糌Îu˜Y
‘æ50‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï OS20-3 –©_ˆê -
TORG0913 2012 ASCO”18099 Naoyuki Nogami Tetsu Shinkai, Toshiyuki Kozuki, Atsuko Ogino, Yuka Kato, Yukio Hosomi, Naoya Hida, Tsuneo Shimokawa, Nobuhiko Seki, HIroaki Okamoto, Masahiko Shibuya, Koshiro Watanabe
‘æ53‰ñ“ú–{”xŠàŠw‰ï‘‰ï O-26 –ìã®”V VŠC“NAãŒŽ–«KA×Œ©K¶Ažw“c’¼–çAŠÖ‡•FA–{ŠÔçŒbA‰ª–{_–¾AàF’J¹•FAX“c’qŽ‹A“n糌Îu˜Y
‘æ10‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï P1-018 ²“¡—º –ìã®”VAVŠC“NAãŒŽ–«KA‰¬–ì“ÖŽqAŽOŠp—S¶A×Œ©K¶AˆäŒû–œ—¢A‰ºìP¶Ažw“c’¼–çAŠÖ‡•FA–{ŠÔçŒbA‰ª–{_–¾AàF’J¹•FAX“c’qŽ‹A“n糌Îu˜Y
TORG1016 ‘æ53‰ñ“ú–{”xŠàŠw‰ï‘‰ï O-272 ‰Á“¡WŽj ‰v“c“TKA”ö‰º•¶_A×Œ©K¶A¼ì³Œ›A“L–؍F”VA‰ª–{_–¾AX“c’qŽ‹A“n糌Îu˜Y
2013”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0808/0913 15th WCLC(IASLCjPoster Naoyuki Nogami Toshiyuki KozukiANaoya HidaAYukio HosomiA Nobuhiko SekiAHiroaki OkamotoAKenji EguchiA Masahiko ShibuyaASatoshi MoritaATetsu ShinkaiA Koshiro Watanabe
TORG0809 "British Journal of CanceriBJCj2013,1-7/doiF10.1038/bjc.2013.378
Advance Online Publication:18 July 2013"
S Niho N.IkedaAH.MichimaeA K.SuzukiA H.SakaiA T.KaburagiA K.MinatoA T.KatoA H.OkamotoA T.SetoA Y.HosomiA K.ShimizuA F.OshitaA H.KunitohA M.TsuboiA M.Takeuchi K.Watanabe
TORG0911 15th WCLC(IASLCj”1385 Poster Kazuhiko Yamada Hideo Khnitoh , Yukio Hosomi , Hiroaki Okamoto , Terufumi Kato , Yuko Komase , Masanori Nishikawa , Satoshi Morita , Koshiro Watanabe
‘æ54‰ñ“ú–{”xŠàŠw‰ï‘‰ïiJLSCjŒû‰‰5 O-21 Â–ì‚Ђë‚Ý ŽR“cˆê•FA×Œ©K¶A‰ª–{_–¾AX“c’qŽ‹Aš “ª‰p•v
TORG1014 ‘æ11‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï(JSMOjOS60F03-085 žw“c’¼–ç žw“c’¼–çA‰ª–{_–¾A×Œ©K¶A‚–Ø—Y—ºA”ö‰º•¶_AŠÖ‡•FA–©_ˆêAš “ª‰p•vAX“c’qŽ‹A“n糌Îu˜Y
15th WCLC(IASLCjposter Makiko Yomota Yukio Hosomi, Yusuke Takagi, Fumihiro Oshita, Kouzo Yamada, Naoya Hida, Hiroaki Okamoto, Nobuhiko Seki, Kouichi Minato, Hideo Kunitoh, Satoshi Morita, Masahiko Shibuya, Koshiro Watanabe
‘æ54‰ñ“ú–{”xŠàŠw‰ï‘‰ïiJLSCjŒû‰‰67 0-331 ŽR“ckŽO ×Œ©K¶A‚–Ø—Y—ºA”ö‰º•¶_Ažw“c’¼–çA‰ª–{_–¾AŠÖ‡•FA–©_ˆêAš “ª‰p•vAX“c’qŽjA“n糌Îu˜Y
TORG1015 2013 ASCO”e19054 Toshiyuki Kozuki Naoyuki Nogami, Hiromoto Kitajima, Tetsu Shinkai, Fumiaki Kato, Emiko Sakaida, Yuichi Takiguchi, Satoshi Ikeda, Masahiro Yoshida, Yasunori Enomoto, Terufumi Kato, Takashi Ogura, Shingo Miyamoto, Satoshi Morita, Koshiro Watanabe
‘æ11‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï(JSMOjOS45F02-104 ‰Á“¡WŽj ãŒŽ–«KA–ìã®”VA’r“cŒdA¬‘q‚ŽuA‘êŒû—TˆêA‹{–{MŒáAX“c’qŽ‹AVŠC“NA“n糌Îu˜Y
‘æ51‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï(JSCOjO-46 ‹{–{MŒá ãŒŽ–«KA–ìã®”VA–k“‡Š°Œ³AVŠC“NAä“cŒb”üŽqA‘êŒû—TˆêA‰|–{‘דTA‰Á“¡WŽjA¬‘q‚ŽuAX“c’qŽ‹A“n糌Îu˜Y
15th WCLC(IASLCjPoster”1487 Toshiyuki Kozuki Naoyuki Nogami, Hiromoto Kitajima, Tetsu Shinkai, Fumiaki Kato, Emiko Sakaida, Yuichi Takiguchi, Satoshi Ikeda, Masahiro Yoshida, Yasunori Enomoto, Terufumi Kato, Takashi Ogura, Shingo Miyamoto, Satoshi Morita, Koshiro Watanabe
‘æ54‰ñ“ú–{”xŠàŠw‰ï‘‰ïiJLSCjŒû‰‰67 0-332 ä“cŒb”üŽq ‘êŒû—TˆêAãŒŽ–«KA–ìã®”VA–k“‡Š°Œ³AVŠC“NA‰|–{‘דTA‰Á“¡WŽjA¬‘q‚ŽuA‹{–{MŒáAX“c’qŽ‹A“n糌Îu˜Y
TORG1016 38Th ESMO Poster Yoshiro Nakahara Terufumi Kato, Noriyuki Masuda, Fumihiro Oshita, Yukio Hosomi, Masanori Nishikawa, Takayuki Kaburagi, Hiroaki Okamoto, Satoshi Morita, Koshiro Watanabe
15th WCLC(IASLCj”1211Mini Oral Ken katono Terufumi Kato, Noriyuki Masuda, Fumihiro Oshita, Yukio Hosomi, Masanori Nishikawa, Takayuki Kaburagi, Hiroaki Okamoto, Satoshi Morita, Kashiro Watanabe,
TORG1017 15th WCLC(IASLCjPoster3.24-014 Yukio Hosomi Masahiko Sibuya, Katsuhiko Naoki, Kenzo Soejima, Naoyuki Nogami, Hiroaki Okamoto, Norihiko Ikeda, Noriyuki Masuda, Masanori Nishikawa, Takashi Seto, Kouichi Minato, Yuichi Takiguchi, Nobuhiko Seki, Fumihiro Oshita, Koshiro Watanabe
2014”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0503 ‘æ12‰ñ“ú–{—Տ°Žîᇊw‰ïi‚i‚r‚l‚nj O3-6 Tsuneo Shimokawa Kaoru Kubota, Hideo Kunitho, Takashi Seto, Naoki Shimada, Masahiro Tsuboi, Hiroaki Okamoto, Noriyuki Masuda, Riichiroh Maruyama, Koshiro Watanabe
TORG0604 ESMO@2014@@Poster#1469 Yuki@Misumi Hiroaki@OkamotoAKatsuhiko@NaokiAYukio@HosomiAYusuke@TakagiATerufumi@KatoANoriyuki@MasudaAAkira@TakakuraAKoichi@MinatoAYosuke@MiuraATakuma@YokoyamaASaori@TakataAKazuma@KishiAMasanori@NishikawaAFumihiro@OshitaANobuhiko@SekiAIsao@GotoAKoshiro@Watanabe
TORG0910 ‘æ12‰ñ“ú–{—Տ°Žîᇊw‰ïi‚i‚r‚l‚nj Poster(P1-16j Shunichiro@Iwasawa Yuichi@TakiguchiAHaruhiro@SaitoAKouzo@YamadaANoriyuki@MasudaAHiroaki@Okamoto@Yukio@HosomiAKazuma@KishiAFumihiro@OshitaAKoshiro@Watanabe
‘æ‚T‚T‰ñ“ú–{”xŠàŠw‰ï‘‰ïiJLSCjPD-92 Îˆä^— ‰ª–{_–¾AâV“¡t—mAŽR“ckŽOA‰v“c“TKA‘êŒû—TˆêA×Œ©K¶AŠÝˆê”nA”ö‰º•¶_A“n糌Îu˜Y
TORG0911 50th@ASCO@2014@General@Poster@#8080 Yoshiro Nakahara Yukio@HosomiA@Kazuhiko@YamadaA@Hiroaki@OkamotoA@Terufumi@KatoA@Yuko@KomaseA@Masanori@NishikawaA@Hideo@KunitohA@Koshiro@Watanabe
TORG1016 Japanese@Journal@of@Clinical@OncologyiJJCOj2014.MayG44i‚TjF497-500.Epub@2014@Mar@28. Satoshi@Ikeda Akimasa@SekineATerufumi@KatoAMasahiro@YoshidaA@Ryo@OgataATomohisa@BabaAKiyotaka@NagahamaA@Koji@OkuderaA@Takashi@Ogura
‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ï@MS70 ‹ß“¡“N˜Y ‰Á“¡WŽjA‰v“c“TKAŽR“ckŽOA×Œ©K¶A¼ì³Œ›A“L–؍F”VA‰ª–{_–¾AX“c’qŽ‹A¬‘q‚ŽuA“n糌Îu˜Y
2015”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0604 ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ï ‰¡ŽR‘ô– ‰ª–{_–¾AŽOŠp—S¶A×Œ©K¶A‰Á“¡WŽjA‰v“c“TKA–©_ˆêA—P–؍Ž•FAŠÝˆê”nA¼ì³Œ›AŒã“¡Œ÷A”ö‰º•¶_AŠÖ‡•FA•ÐãM”VA“n糌Îu˜Y
TORG0604 16th@WCLC(IASLCjPoster Terufumi Kato -
TORG0910 ANTICANCER@RESEARCH35 Kouzo Yamada Haruhiro Saito, Tetsuro Kondo, Shuji Murakami, Noriyuki Masuda, Michiko Yamamoto, Satoshi Igawa, Ken Katono, Yuichi Takiguchi, Shunichiro Iwasawa, Ryota Kurimoto, Hiroaki Okamoto, Tsuneo Shimokawa, Yukio Hosomi, Yusuke Takagi, Kazuma Kishi, Mari Ohba, Fumihiro Oshita, Koshiro Watanabe
TORG0911 Europian@Journal@of@Cancer i2015j,pp.19041-1910 Kazuhiko@Yamada Hiromi Aono, Yukio Hosomi, Hiroaki Okamoto, Terufumi Kato, Yuko Komase, Masanori Nishikawa, Koichi Azuma, Hiroaki Takeoka, Yusuke Okuma, Yoshiro Nakahara, Akira Sato, Mari S.Oba, Satoshi Morita, Hideo Kunitoh, Koshiro Watanabe
TORG1014 BMC@Cancer (2015)15:740 DOI 10.1186/s12885-015-1756-1 Yusuke Takagi Yukio Hosomi, Fumihiro Oshita, Hiroaki Okamoto, Nobuhiko Seki, Koichi Minao, Hiromi Aono, Kouzo Yamada, Yusuke Okuma, Naoya Hida, Takahiko Sakamoto, Yosuke Miura, Makiko Yomota, Akira Satoh, Hideo Kunitoh, Kentaro Sakamaki, Masahiko Shibuya, Koshiro Watanabe
TORG1018 ‘æ56‰ñ“ú–{”xŠàŠw‰ï‘‰ïiJLSCjO- 066 “c’†—mŽj ‰ºìP¶A‰ª–{_–¾AŽR“cˆê•FA‹v•Û“cŠ]AŠÝˆê”nA”ö‰º•¶_A‘êŒû—TˆêA×Œ©K¶A‰Á“¡WŽjA–ìã®”VA‘“c“TKAŽR’†’|tA“n糌Îu˜Y
TORG1323 16th@WCLC(IASLCjPoster3.01- 085 Toshiyuki Kozuki Naoyuki Nogami, Natsumi Yamashita, Tetsu Shinkai, Takehito Shukuya, Nobuhiko Seki, Terufumi Kato, Miyako Satouchi, Noriyuki Masuda, Koshiro Watanabe
2016”N“x
ŽŽŒ±”ԍ† ˜_•¶/Šw‰ï–¼/Session Type •M“ª‰‰ŽÒ–¼ ‹¤“¯‰‰ŽÒ–¼
TORG0604 ‘æ14‰ñ“ú–{—Տ°Žîᇊw‰ïiJSMOjPoster Makoto Nagamata Yukio Hosomi, Yuki Misumi, Hiroaki Okamoto, Terufumi Kato, Noriyuki Masuda, Koichi Minato, Takuma Yokoyama, Katsuhiko Naoki, Koshiro Watanabe
TORG0809 41Th@ESMOF2016@Poster Seiji Niho Norihiko Ikeda, Hiroshi Michimae, Kenji Suzuki, Hiroshi Sakai, Takayuki Kaburagi, Katsuo Yoshiya, Koichi Minato, Terufumi Kato, Hiroaki Okamoto, Takashi Seto, Yukio Hosomi, Kimihiro Shimizu, Haruhiro Saito, Masanori Tsuchida, Hideo Kunitoh, Masahiro Tsuboi, Masahiro Takeuchi, Koshiro Watanabe
TORG1015 BMC@Canceri2016j16F306@DOI@10.1186/‚“12885-016-2338-6 Toshiyuki Kozuki Naoyuki Nogami, Hiromoto Kitajima, Shunichiro Iwasawa, Emiko Sakaida,@Yuichi Takiguchi, Satoshi Ikeda, Masahiro Yoshida, Terufumi Kato, Shingo Miyamoto, Kentaro Sakamaki, Tetsu Shinkai, Koshiro Watanabe
TORG1018 ‘æ14‰ñ“ú–{—Տ°Žîᇊw‰ïiJSMOjO3-9-5 Haruhiro Saito Hiroshi Tanaka, Tsuneo Shimokawa, Hiroaki Okamoto, Kazuhiko Yamada , Kaoru Kubota, Kazuma Kishi, Yuichi Takiguchi, Yukio Hosomi, Terufumi Kato, Koshiro Watanabe
17th@WCLCiIASLCj:@Poster Kazuhiko Yamada Tsuneo Shimokawa, Hiroaki Okamoto, Hiroshi Tanaka, Kaoru Kubota, Kazuma Kishi, Haruhiro Saito, Yuichi Takiguchi, Yukio HOsomi, Terufumi Kato, Daijiro Harada, Noriyuki Masuda, Hisashi Kasai, Yoichi Nakamura, Koichi Minato, Takayuki Kaburagi, Katsuhiko Naoki, Koji Hikino ,Takeharu Yamanaka, Koshiro Watanabe
TORG1424 17th@WCLCiIASLCj:@Poster Satoshi Ikeo Naoyuki Nogami, Hiromoto Kitajima, Hiroshige Yoshioka, Akihiro Bessho, Kyoichi Kaira, Toshio Kubo, Shuji Murakami, Koshiro Watanabe, Katsuyuki Kiura
ESMO-Asia 2016 Poster Akihiro Bessho Naoyuki Nogami, Toshio Kubo, Hiromoto Kitajima, Satoshi Ikeo, Kyoichi Kaira, Shinobu Hosokawa, Hiroshige Yoshioka, Shuji Murakami Koshiro Watanabe, Katsuyuki Kiura
TORG1426 ‘æ14‰ñ“ú–{—Տ°Žîᇊw‰ïiJSMOj Poster Žsì–õŽq ŠÖ‡•FA•ÊŠºGA‰ª–{_–¾A‰v“c“TKA×Œ©K¶A‘êŒû—TˆêAŠÝˆê”nA¼‘º®ŽuAŠ}ˆä®


ƒy[ƒWƒgƒbƒv‚Ö